Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin-conjugating enzyme E2 S (UBE2S) is a member of the E2 ubiquitin-conjugating enzyme family, catalyzing the attachment of ubiquitin to substrate proteins. UBE2S is a key component of the anaphase-promoting complex/cyclosome (APC/C), controlling cell cycle progression through mitosis by elongating Lys-11-linked polyubiquitin chains on specific substrates, thereby targeting them for proteasomal degradation and promoting mitotic exit. It also modulates the stability of important signaling proteins such as β-catenin, enhancing their accumulation via K11-linked polyubiquitination and activating the Wnt/β-catenin pathway. UBE2S is overexpressed and functionally implicated in various cancers, where it contributes to malignant cell proliferation, migration, and poor prognosis. Inhibitors of related pathways, such as ETC-159, may indirectly target UBE2S function[1][3][5][7][8].
Inhibition of Wnt/β-catenin pathway, Potential inhibition of K11-linked polyubiquitination activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin-conjugating enzyme E2 S (UBE2S).